Welcome to Otsuka Pharmaceutical Development & Commercialization, Inc.

Contact us | Search Site | Site Map

This is a spacer image

Contact:

Corporate Communications
or by mail:
Corporate Communications
Otsuka America Pharmaceutical, Inc.
2440 Research Boulevard
Rockville, MD 20850 USA


Font Size:

February 25, 2009

Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka�s Pharmaceutical Business Worldwide

September 4, 2008

September 4, 2008: Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration

September 4, 2008

September 4, 2008: Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye

August 26, 2008

Otsuka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic

June 25, 2008

U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia

May 8, 2008

ABILIFY� (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia

May 8, 2008

U.S. Food and Drug Administration Approves ABILIFY� (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features

March 10, 2008

Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex

December 21, 2007

New Drug Application for Tolvaptan, Otsuka�s Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration

December 17, 2007

Otsuka Pharmaceutical, Co., Ltd. Acquires Rights to IV Busulfex from PDL Biopharma, Inc.

September 19, 2007

ECLIPSE Data on Effects of Otsuka�s Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients� Hemodynamics and Urine Output Featured in Heart Failure Society of America�s Late Breaking Trials

July 17, 2007

ABILIFY� (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food and Drug Administration for Adjunctive Treatment in Adults with Major Depressive Disorder

June 5, 2007

ABILIFY� (aripiprazole) Supplemental New Drug Application for Pediatric Patients with Schizophrenia Accepted for Priority Review by the U.S. Food and Drug Administration

May 23, 2007

Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents with Schizophrenia

May 21, 2007

Six-Week Investigational Study in Adults with Major Depressive Disorder Evaluates the Effectiveness of Adjunctive Aripiprazole Therapy with Antidepressants

March 25, 2007

EVEREST Data on Short- and Long-Term Use of Otsuka�s Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC�s Late Breaking Clinical Trials

January 23, 2007

Otsuka Pharmaceutical Co., Ltd. Announces Establishment of New Organization

November 16, 2006

New Data On Otsuka�s Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting

May 25, 2006

Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care in Management of Community-Treated Patients with Schizophrenia

May 25, 2005

New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia

May 18, 2005

Multiple Studies at DDW Report on Adacolumn^� Apheresis Device in Treating Inflammatory Bowel Disease

November 9, 2004

Poster on Investigational Otsuka Product Receives Presidential Poster Award from American College of Gastroenterology

May 18, 2004

Data Presented at Digestive Disease Week on Two Otsuka Products In Development for Inflammatory Bowel Disease

April 15, 2004

Dr. Ralph Harkins Joins Otsuka Maryland Research Institute, Inc. as Vice President, Biometrics

November 10, 2003

Otsuka's Tolvaptan Decreased Fluid Retention in Hospitalized Patients with Worsening Congestive Heart Failure

September 2, 2003

MR. Yoichi Nishinakamura Joins Otsuka Maryland Research Institute, Inc. as Chairman and Chief Executive Officer

July 22, 2003

Otsuka Initiates Phase III Clinical Trials on Compound for Ulcerative Colitis

October 31, 2002

'Control valve' within heart cells could protect body during heart attacks.

* OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.

0109W-0602